论文部分内容阅读
:目的 通过对肺癌组织雌 /孕激素受体表达的测定 ,从病理特征、超微结构及内分泌治疗方面进行初步探讨。方法 应用免疫组织化学 SP法检测 40例肺癌和 10例肺良性病变组织雌 /孕激素受体表达 ,并结合临床病理、超微结构 ,部分肺癌患者辅以三苯氧胺治疗。结果 肺癌组织中雌激素受体 (estrogen receptor,ER)阳性率为5 7.5 % ,孕激素受体 (progesterone receptor,PR)阳性率为 40 .0 % ,受体阳性率与组织学分级呈负相关 ,且与病理类型有关 ,与分期、肿块直径、性别无关 ;电镜亦证实 ER阴性者更具恶性特征 ;三苯氧胺对 ER阳性肺癌患者有效。结论 肺癌组织中存在雌 /孕激素受体的表达 ,并能反映肺癌的生物学行为 ;三苯氧胺对 ER阳性肺癌患者是一安全有效的内分泌治疗药物
OBJECTIVE: To investigate the expression of estrogen/progesterone receptors in lung cancer and to explore the pathological features, ultrastructure and endocrine therapy. Methods The expression of estrogen and progesterone receptors in 40 cases of lung cancer and 10 cases of benign lung lesions were detected by immunohistochemical SP method. Combined with clinicopathology, ultrastructure, some lung cancer patients were treated with tamoxifen. Results The positive rate of estrogen receptor (ER) in lung cancer was 57.5%, and the positive rate of progesterone receptor (PR) was 40.0 %. The positive rate of receptor was negatively correlated with histological grade. , And with the type of pathology, and staging, diameter of the mass, gender has nothing to do; electron microscopy also confirmed that ER negative more malignant characteristics; tamoxifen for ER positive lung cancer patients. Conclusion The expression of estrogen and progesterone receptors in lung cancer tissues can reflect the biological behaviors of lung cancer. Tamoxifen is a safe and effective endocrine therapy for ER positive lung cancer patients.